291 related articles for article (PubMed ID: 37614311)
1. Progress of research on molecular targeted therapies for colorectal cancer.
Huang S; Ye J; Gao X; Huang X; Huang J; Lu L; Lu C; Li Y; Luo M; Xie M; Lin Y; Liang R
Front Pharmacol; 2023; 14():1160949. PubMed ID: 37614311
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.
Li F; Lin Y; Li R; Shen X; Xiang M; Xiong G; Zhang K; Xia T; Guo J; Miao Z; Liao Y; Zhang X; Xie L
Front Pharmacol; 2023; 14():1165666. PubMed ID: 37927605
[TBL] [Abstract][Full Text] [Related]
4. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
[TBL] [Abstract][Full Text] [Related]
5. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
7.
Li ZN; Zhao L; Yu LF; Wei MJ
Gastroenterol Rep (Oxf); 2020 Jun; 8(3):192-205. PubMed ID: 32665851
[TBL] [Abstract][Full Text] [Related]
8. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
9. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives.
Personeni N; Smiroldo V; Giunta EF; Prete MG; Rimassa L; Bregni G; Sclafani F
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572729
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer.
Kocoglu H; Velibeyoglu FM; Karaca M; Tural D
World J Gastrointest Oncol; 2016 Jan; 8(1):1-7. PubMed ID: 26798432
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer.
Rawla P; Barsouk A; Hadjinicolaou AV; Barsouk A
Med Sci (Basel); 2019 Jul; 7(8):. PubMed ID: 31366129
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment.
Gmeiner WH
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473386
[TBL] [Abstract][Full Text] [Related]
13. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
14. HER2 targeted therapy in colorectal cancer: New horizons.
Suwaidan AA; Lau DK; Chau I
Cancer Treat Rev; 2022 Apr; 105():102363. PubMed ID: 35228040
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
[TBL] [Abstract][Full Text] [Related]
18. HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study.
Fraga T; de Sousa MJ; Magalhães J; Basto R; Paulo J; Bonito N; Magalhães JP; Figueiredo P; Sousa GM
Cureus; 2023 Jul; 15(7):e42536. PubMed ID: 37637599
[TBL] [Abstract][Full Text] [Related]
19. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698
[TBL] [Abstract][Full Text] [Related]
20. Immune Resistance and EGFR Antagonists in Colorectal Cancer.
Giordano G; Remo A; Porras A; Pancione M
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
